Deals this week: Aspen Global Incorporated, Zhejiang Conba Pharmaceutical, Teva Pharmaceutical Indus

Mauritius-based holding company Aspen Global Incorporated (AGI) has signed an agreement with AstraZeneca to acquire the rights to the latter’s anaesthetic treatments portfolio for $555m.

AstraZeneca will receive performance-related milestones of up to $211m from AGI between 1 September 2017 and 30 November 2019. The company will also produce the anaesthetic treatments during the transition period.

The divestment will improve the efficiencies of both companies.

Chinese pharmaceutical company Zhejiang Conba Pharmaceutical plans to raise CNY1.5bn ($228.81m) through a public offering of medium-term notes.

The company plans to use the funds for working capital purposes.

Israeli pharmaceutical company Teva Pharmaceutical Industries has signed an agreement with US-based pharmaceutical company Nuvelution Pharma to develop AUSTEDO (deutetrabenazine) tablets.

Nuvelution Pharma will handle the clinical development of the drug, while Teva Pharma will be responsible for the regulatory process and commercialisation, under the agreement.

Chinese pharmaceutical products manufacturer Kangmei Pharmaceutical has announced the completion of the third tranche of a public offering of 5.47% medium-term notes due 2022 to raise CNY2bn ($304.74m).

Chinese pharmaceutical company Zhejiang Huahai Pharmaceutical plans to raise CNY1.8bn ($274.6m) through a public offering of convertible bonds due 2023.